Skip to content

LBRX LBRX Other Income (Expense)

Other Income (Expense) at other companies

Alkermes logo
AlkermesALKS
-$13.65M-217%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$1.36M+248%
Alto Neuroscience logo
Alto NeuroscienceANRO
$901K+77.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$7.34M-313%
Opko Health logo
Opko HealthOPK
-$9.94M-60.2%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$542K-7.8%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's other income (expense)?
LBRX (LBRX) reported other income (expense) of $3.05M in Q1 2026.
How has LBRX's other income (expense) changed year-over-year?
LBRX's other income (expense) increased by 171.6% year-over-year, from $1.12M to $3.05M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.